4 Healthcare Stocks With Massive Gains—and More to Come Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year. MarketBeat · Mar 29, 2025
Why are users of 23andMe being urged to delete their data? Genetic testing company’s bankruptcy proceedings could result in auction of the genetic data of 15 million users. Al Jazeera · Mar 26, 2025
Pharma Frenzy: Volatility Ignites Biotech Sector Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value. MarketBeat · Mar 25, 2025
Banks drag back early gains as local shares edge higher The Australian share market has given up more than half its early session gains but finished slightly higher, after a dramatic about-face in financials stocks. AAP · Mar 25, 2025
Man who claimed Roundup caused his cancer awarded $2.1billion The verdict marks the latest in a long-running series of court battles Monsanto has faced over its Roundup herbicide The Independent UK · Mar 23, 2025
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock MarketBeat · Mar 23, 2025
AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing Pharma company will invest money over five years in ‘strategic partnership’ after ditching UK expansion The Guardian - UK · Mar 21, 2025
UK pharmacies could cut hours unless NHS provides ‘new and sufficient’ funding The National Pharmacy Association has recommended collective action for the first time in its history The Guardian - UK · Mar 18, 2025
AMD manager reports 45% GPU retail market share in Japan — Eyes 70% as the next target AMD marketing manager Yoshiaki Sato reported that Radeon GPUs have accounted for 45% of GPU sales in Japan, presumably since RDNA 4 launched. Tom’s Hardware · Mar 17, 2025
AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’ UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug The Guardian - UK · Mar 17, 2025
Ireland could lose pharma tax to US after Trump accusations, experts warn Predictions that US firms could retain manufacturing plants in Ireland but move profits back to America The Guardian - UK · Mar 13, 2025
These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Dividend stocks aren't just for long-term income generation. These three shares have jumped 15% in one month while also offering dividend payouts. MarketBeat · Mar 11, 2025
CVS is opening more standalone pharmacies after shuttering 1,000 stores CVS will open a dozen new stores, but they’ll be half the size of a typical location The Independent UK · Mar 10, 2025
Raspberry Pi powers briefcase-sized PiEEG 'Bio Lab' project Blink twice to control the robot arm Tom’s Hardware · Mar 10, 2025
MarketBeat · Mar 10, 2025 Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.
Evening Standard · Mar 10, 2025 Alliance Pharma agrees £362m takeover by biggest shareholder The deal will see shareholders get 64.75p a share, up from the original offer worth 62.5p a share, or £349.7 million.
Evening Standard · Mar 6, 2025 Why neurohacking is the new biohacking Brain training just got an upgrade: neurohacking is the latest wellness microtrend, but is there a way to do it without breaking the bank?
MarketBeat · Mar 6, 2025 Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?
MarketBeat · Mar 3, 2025 These S&P 500 Stocks Have Low P/E Ratios — Time to Buy? This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys.
Latin Times · Mar 2, 2025 Marjorie Taylor Greene Claims 'Bio Labs' in Ukraine Are Using 'Dr. Frankenstein Science' to Create Diseases and Vaccines Rep. Marjorie Taylor Greene weighed in on a mystery disease outbreak, suggesting global bio labs, including in Ukraine, are sinisterly engineering diseases.
Windows Central · Mar 1, 2025 Skip NVIDIA — Why AMD’s new gaming GPU is my next upgrade, and why it should be yours, too AMD revealed its next-gen RDNA 4 graphics cards, and the info available so far is enough for me to make a final decision on my next PC upgrade.
The Guardian - UK · Feb 28, 2025 British pharma company GSK pauses diversity work citing Trump orders London-based FTSE 100 firm reviewing its policies, saying it is obliged to comply because US is its No 1 market
MarketBeat · Feb 27, 2025 Regeneron: Is It the Perfect Biotech Stock for Value and Growth? Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.
The Guardian - UK · Feb 26, 2025 Covid inquiry to hear evidence about Michelle Mone-linked firm in private Chair rules that details about PPE contracts given to company linked to Tory peer will be heard in closed session
MarketBeat · Feb 26, 2025 Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval? Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.